View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 12, 2018

Medtronic initiates Onyx ONE Clear study in Japan and US

Medtronic has initiated a new clinical study in patients implanted with its Resolute Onyx drug-eluting stent (DES) during percutaneous coronary intervention (PCI) procedures.

Medtronic has initiated a new clinical study in patients implanted with its Resolute Onyx drug-eluting stent (DES) during percutaneous coronary intervention (PCI) procedures.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The Resolute Onyx DES secured the European CE-Mark and the US Food and Drug Administration (FDA) approval in September 2014 and April 2017, respectively.

The Onyx ONE Clear study will assess the use of one-month dual antiplatelet therapy (DAPT) in US and Japanese patients who are at high risk of bleeding.

DAPT is a combination of aspirin and an anti-clotting drug. The study will evaluate its safety, such as any potential cardiac risks, when used with a next-generation DES.

“The Onyx ONE Clear study will assess the use of one-month dual antiplatelet therapy (DAPT) in US and Japanese patients who are at high risk of bleeding.”

Onyx ONE Clear study co-principal investigator David Kandzari said: “This large-scale clinical study will help address an unmet need as high bleeding risk patients have been largely underrepresented in previous studies looking at shorter DAPT duration.”

This study is part of the Medtronic Onyx ONE Month DAPT Program, which also included a prior Onyx ONE Global Study. The DAPT programme is designed to recruit a total of about 2,700 patients across 140 clinical sites globally.

Onyx ONE Month DAPT Program chair Gregg Stone said: “One-month DAPT duration after coronary stenting in high bleeding risk patients offers the potential to substantially enhance the safety of interventional procedures in these high-risk patients.

“This study will provide insight as to whether one-month DAPT after Resolute Onyx in high bleeding risk patients is effective in minimising stent thrombosis and other complications, thereby reducing bleeding-related harm with prolonged anti-platelet therapy.”

Medtronic said that more than 20,000 patients in its clinical trials have addressed DAPT duration.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network